<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00139685</url>
  </required_header>
  <id_info>
    <org_study_id>Z54000261</org_study_id>
    <nct_id>NCT00139685</nct_id>
    <nct_alias>NCT00264836</nct_alias>
  </id_info>
  <brief_title>Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception</brief_title>
  <official_title>Depo-Provera: Evaluation of Bone Mineral Density and Total Body Calcium in Adolescent DP 150 CI Users and Matched Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive
      Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and
      following discontinuation of DMPA. Another group electing non-hormonal contraception or
      abstinence will be recruited as a reference population, across all study sites. The primary
      variable is BMD, measured by Dual Energy X-ray Absorptiometry (DXA). Secondary variables are:
      Total Body Composition&amp; Total Body Calcium (TBC), measured by Dual Energy X-ray
      Absorptiometry (DXA), and surrogate biologic BMD markers. Safety will be evaluated by adverse
      event reporting, laboratory evaluations, pregnancies, weight and vital signs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Bone Mineral Density in adolescent Depo-Provera Contraceptive</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection (DP150CI) users will be evaluated and compared during depo</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>medroxyprogesterone acetate (DMPA) therapy and following discontinuation of</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>DMPA.Another group electing non-hormonal contraception or abstinence is</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>recruited as a reference population, across all study sites.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary variables are: Total Body Composition &amp; Total Body Calcium (TBC),</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measured by Dual Energy X-ray Absorptiometry (DXA)Surrogate biologic BMD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>markers</measure>
  </secondary_outcome>
  <enrollment>350</enrollment>
  <condition>Contraception</condition>
  <condition>Bone Density</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo-Provera Contraceptive Injection - DP150CI</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescent females who have had any menses in the 6 months prior to enrollment

          -  Must have a negative pregnancy test

        Exclusion Criteria:

          -  Concomitant medication exclusion use of bone modifying agents, glucocorticoids,
             heparin, and anticonvulsants

          -  Screening Spinal BMD with z score not greater than -2 of matched young normals
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=Z54000261&amp;StudyName=Depo%2DProvera%3A+Evaluation+of+BMDensity+and+Total+Body+Ca+Adolescent+DP150CI+Users+and+Non%2Dhormonal+Contraception</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2005</study_first_posted>
  <last_update_submitted>September 23, 2008</last_update_submitted>
  <last_update_submitted_qc>September 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

